Introducing carbon quantum dot-Capivasertib drug carrier complex for enhanced treatment of breast cancer.
Capivasertib (AZD5363) is a 2023 FDA-approved pyrrolopyrimidine-derived compound that treats hormone receptor positive, HER2 negative metastatic breast cancer in adult patients. It is a novel pan-AKT kinase catalytic inhibitor in ER + breast cancer cell lines, including MCF7. The dominant influence...
| Published in: | PLoS ONE |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Online Access: | https://doi.org/10.1371/journal.pone.0319206 |